Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations

Introduction: V600E BRAF mutation is an established driver mutation in a variety of tumors. Vemurafenib is a selective inhibitor of the BRAF V600E kinase, known to be highly effective in BRAF V600E-positive metastatic melanoma. As a single agent, vemurafenib is relatively ineffective in other V600E-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Ther
Autors principals: Ofir Dovrat, Tali, Sokol, Ethan, Frampton, Garrett, Shachar, Eliya, Pelles, Sharon, Geva, Ravit, Wolf, Ido
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Bedside to Bench Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6300338/
https://ncbi.nlm.nih.gov/pubmed/30036146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1480289
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars